Shots: The approval is based on the P-II JULIET (NCT02445248) trial results assessing Kymriah (tisagenlecleucel) in patients with 1L+ DLBCL and followed by NICE approval in for pediatric and aged <25 yrs. with B-cell acute lymphoblastic leukemia (ALL) in Sep,2018 The P-II JULIET results; 18mos.@ median relapse-free survival rate 64%; OR 43%; safe and effective […]Read More
Shots: Post FDA approval in 2017, Yescarta (axicabtagene ciloleucel) receives EU marketing approval for the treatment of Relapsed or Refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) The approval is based on ZUMA-1 trial with (N=101) results: 72%( 73/101) responded to therapy; 51%(52/101) achieved complete response; with one-year infusion- 60% […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
